P

Piyong Sola

National Institute of Pharmaceutical Education and Research

Research areas: Medicine · Neurology · Parkinson's Disease Mechanisms and Treatments · Nanoparticle-Based Drug Delivery · Advanced Drug Delivery Systems

ORCID iD 0000-0003-3503-7316

Employment

Education

Education history is unavailable.

Projects & Funding

Projects & funding information is unavailable.

Publications (26)

  • An insightful infrared spectroscopic analysis of rutin: the trajectory of method development and assessment for environmental sustainability using white and green analytical chemistry
    Journal of the Iranian Chemical Society 2026 DOI: 10.1007/s13738-026-03352-x
    +Save
  • Molecular mirror: reflecting the complexity of Parkinson’s disease
    Neurological Sciences 2026 DOI: 10.1007/s10072-026-08921-9
    +Save
  • An insightful infrared spectroscopic analysis of rutin: the trajectory of method development and assessment for environmental sustainability using white and green analytical chemistry.
    Journal of the Iranian Chemical Society. 2026
    +Save
  • Development of a green chemistry based bioanalytical method using response surface methodology to analyze febuxostat and indomethacin in rabbit plasma
    Scientific Reports 2026
    +Save
  • Molecular mirror: reflecting the complexity of Parkinson’s disease
    Neurological Sciences 2026
    +Save
  • Unveiling the therapeutic potential of Farnesol against Parkinson’s disease: insights from molecular Docking and animal studies
    DARU Journal of Pharmaceutical Sciences 2026
    +Save
  • Recent Advances in Marine-Derived Nanoformulation for the Management of Glioblastoma
    Molecular Biotechnology 2025 DOI: 10.1007/s12033-024-01287-3
    +Save
  • c-Abl Inhibitors in Parkinson's: Exploring Hypotheses on Alpha-Synuclein Modulation
    Advanced Pharmaceutical Bulletin 2025 DOI: 10.34172/apb.42806
    +Save
  • Computational phytochemical screening for Parkinson's disease therapeutics: c-Abl and beyond
    Computational Biology and Chemistry 2025
    +Save
  • Roflumilast-loaded nanostructured lipid carriers attenuate oxidative stress and neuroinflammation in Parkinson’s disease model
    Journal of drug targeting 2025
    +Save
  • c-Abl inhibitors in Parkinson’s: Exploring hypotheses on alpha-synuclein modulation
    Advanced Pharmaceutical Bulletin 2025
    +Save
  • An Analytical Approach by Tri-Combination of Gradient UFLC, Response Surface Methodology and Green Chemistry Principle for Simultaneous Quantification of Azelnidipine and Chlorthalidone in Rabbit Plasma
    Journal of Chromatographic Science 2024
    +Save
  • Current advances in the treatment of Parkinson’s disease based on nanotechnology
    Futuristic Trends in Pharmacy & Nursing 2024
    +Save
  • Development of a gradient method for sulfamethoxazole, trimethoprim, isoniazid, and pyridoxine hydrochloride in rabbit plasma through QbD-driven investigation
    Scientific reports 2024
    +Save
  • Recent Advances in Marine-Derived Nanoformulation for the Management of Glioblastoma
    Molecular Biotechnology 2024
    +Save
  • Targeted delivery of DAPT using dual antibody functionalized solid lipid nanoparticles for enhanced anti-tumour activity against triple negative breast cancer
    International Journal of Pharmaceutics 2024
    +Save
  • Herbal Drug Standardization: A Systemic Review
    Journal of Drug Delivery and Therapeutics 2023
    +Save
  • Phosphodiesterase-4 inhibition in Parkinson’s disease: molecular insights and therapeutic potential
    Cellular and Molecular Neurobiology 2023
    +Save
  • Polysorbate 80 surface modified SLNs of formoterol suppress SNCA gene and mitochondrial oxidative stress in mice model of Parkinson’s disease
    Scientific Reports 2023
    +Save
  • Neuroprotective approaches to halt Parkinson's disease progression
    Neurochemistry International 2022
    +Save